Please login to the form below

Not currently logged in

Court blocks EMA release of pharma company data

AbbVie and InterMune successfully challenge request for trial data for Humira and Esbriet

Court blocks EMA release of pharma company dataAbbVie and InterMune have blocked a European Medicines Agency (EMA) bid to release clinical data about their drugs following a ruling by the General Court of the EU, although the regulator says it may appeal.

The two companies sought the injunction earlier this year after the EMA said it had received requests for data under its access-to-documents programme, part of a transparency drive initiated by the agency in 2010.

The case has focused attention on a row between the EMA, transparency advocates and the drug industry on what constitutes commercially confidential information.

To date, the regulator has granted access to 1.9 million pages of data filed by pharma companies as part of marketing authorisation applications (MAAs) in response to freedom of information requests, but AbbVie and InterMune are the first to legally challenge the new policy.

AbbVie's objection centres on requests for data on its rheumatoid arthritis drug Humira (adalimumab), while InterMune - whose only marketed product is idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) - is trying to block access to information sought by academic researchers.

Their position is backed by industry groups, including the European Federation of Pharmaceutical Industries and Associations (EFPIA) which has warned that the interests of drug developers could be significantly harmed if data is released indiscriminately. In the opposing camp are those who claim the industry's aversion to transparency is damaging both to patient health and to pharma companies' reputations.

US trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) said that while its members "support responsible data sharing that protects patient privacy, maintains the integrity of the regulatory review process, and preserves incentives for biomedical research", the EMA's policies "fail to respect these principles".

The EMA said in a defiant statement that it remains committed to "transparency and openness of information to meet the legitimate public interests to enable scrutiny of the agency's recommendations on medicines" and would continue to operate the access-to-documents programme on a case-by-case basis.

More contention to come?
The transparency debate looks set to become even more contentious in the coming months, given that the EMA pledged last year to proactively publish trial data - once a drug has completed the marketing-authorisation process - by the start of 2014.

At the same time as announcing the EU court decision, the EMA published final advice from advisory groups set up to help it draft the policy and would be pressing ahead with the plans, pledging to develop a system that "ensures transparency in the best interest of public health without impinging on the company's intellectual property rights".

A draft policy will be published in July and finalised in November, said the regulator.

1st May 2013

From: Research, Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...